Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05906420
Other study ID # pc-ASTRAL
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2003
Est. completion date August 31, 2023

Study information

Verified date June 2023
Source University of Thessaly
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to develop a prognostic score for ischemic posterior circulation strokes, based on our previous work on with the ASTRAL scores (Acute STroke Registry and Analysis of Lausanne) on overall stroke prognosis, intracranial occlusion, recanalization and stroke recurrences. The main question it aims to answer is the modified Rankin score in 3 months after the event. Participants will be patients with acute ischemic stroke of the posterior circulation with mRS priot to event <3. All the data will be collected retrospectively from patients included in the ASTRAL registry between January 2003 and December 2021. The ASTRAL registry will be used as the derivation cohort of the score. Demographics, acute glucose, NIHSS score and acute imaging of each participant will be used from the derivation cohort in order to create an integer-based prognostic score. After internal validation, we plan to validate the score in external stroke registries to show its validity.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2000
Est. completion date August 31, 2023
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Isolated posterior circulation strokes based on clinical or/and imaging evidence. - Arriving within 24h at hospital since last proof of good health. Exclusion Criteria: - no available data for 3 months modified Rankin Score - modified Rankin Score=3 prior the event

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
ASTRAL prognostic score
ASTRAL prognostic score

Locations

Country Name City State
Greece Medical School, University of Thessaly, Larissa University Hospital Larissa Thessaly
Switzerland Stroke Center, Department of clinical neurosciences, Lausanne University Hospital and University of Lausanne Lausanne Vaud Canton

Sponsors (2)

Lead Sponsor Collaborator
University of Thessaly University of Lausanne

Countries where clinical trial is conducted

Greece,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary 3 months modified Ranking scale evaluation of 3 months neurological disability January 2003-December 2021
See also
  Status Clinical Trial Phase
Recruiting NCT06312540 - PERSonalized rObotic NeurorehAbilitation for Stroke Survivors
Not yet recruiting NCT06315192 - Stroke Alarm Efficacy Trial N/A
Completed NCT02111564 - A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Phase 3
Completed NCT02430324 - The Multicenter Italian INCEPT (INfarto CErebrale Post-Traumatico) Study N/A
Not yet recruiting NCT06320431 - ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Phase 3